ClinicalTrials.gg
RecruitingNCT06991361EVENTUpdated Nov 4, 2026

Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD

A Phase 1 interventional study of EVE-Treg in Graft Versus Host Disease (cGvHD), sponsored by Sarah Nikiforow, MD. Recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionBronchiolitis Obliterans SyndromeRegistry: Graft vs Host DiseaseReclassifiedWhy we changed it
Registry
Graft vs Host Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Bronchiolitis Obliterans Syndrome
Why
  1. The study's title name Bronchiolitis Obliterans Syndrome, a narrower term within Graft vs Host Disease.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sarah Nikiforow, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 29, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 70 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Planned enrollment
191st of 260
21 · median 45
Started
2026
with 12 others
Phase 1
30 of 300
5 open now
Primary completion
2029-05
later than 57 of 68 live
Registered
283rd of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 191st largest by planned enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2026, is one of 30 in phase 1, reaches primary completion later than 57 of the 68 other live ones, and was the 283rd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well. However, HCT can cause serious, sometimes life-threatening complications.

One of the most serious and common complications of HCT is graft-versus-host disease (GVHD). GVHD can appear early after the transplant, usually about 3 to 4 weeks after the transplant is given. This is called acute GVHD (aGVHD), because it usually happens over a couple of days. If successfully treated, acute GVHD quickly goes away. Sometimes GVHD happens months after the transplant. Then it is called chronic GVHD (cGVHD), because it happens gradually and goes away slowly.

The investigators are doing this study to see if one dose of Ex vivo-Expanded Regulatory T cells (EVE-Treg) can be used together with the daily Interleukin 2 (IL-2) to treat cGVHD, that has not responded to steroid treatment or low-dose IL-2.

03

Conditions studied

  • Graft Versus Host Disease (cGvHD)

Browse trials for

04

In context

Bronchiolitis Obliterans Syndrome Reclassified

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

This study's planned enrollment of 21 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.

Browse Bronchiolitis Obliterans Syndrome studies →

Lead sponsor

This is the only study on the registry with Sarah Nikiforow, MD as lead sponsor.

Compared within Bronchiolitis Obliterans Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Graft vs Host Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipient of 7-8/8 HLA-matched hematopoietic stem cell transplantation or recipient of haploidentical allogenic hematopoietic stem cell transplantation.
  • Age 2 and up.
  • Must have - chronic that is still active despite at least 4 weeks of treatment with low-dose subcutaneous (SC) IL-2.
  • Stable dose of glucocorticoids for 2 weeks prior to enrollment
  • no addition or subtraction of other medications for 4 weeks prior to enrollment.
  • Must have adequate organ and marrow function.
  • Ability to understand and willingness to sign a written form.
  • Donor who is willing and cleared to donate starting material for manufacture of EVE-Treg.

Exclusion criteria

Exclusion Criteria:

  • Recipient of umbilical cord blood stem cell graft.
  • Ongoing prednisone requirement greater than 1 mg/kg/day (or equivalent).
  • /Lansky performance score less than 40%.
  • Concurrent use of methotrexate, azathioprine, or a calcineurin-inhibitor plus sirolimus.
  • Other agents within 4 weeks prior to enrollment.
  • Participants with post-transplant exposure to donor lymphocyte infusion, or T-cell or IL-2 targeted medications within 100 days prior to enrollment.
  • Participants with new immunosupprssive medication, extra-corporeal photopheresis or rituximab therapy initiated int he 4 weeks prior to enrollment.
  • Participants with active malignant relapse or recrudescence of their prior hematologic disorder.
  • Uncontrolled intercurrent illness unrelated to cGVHD.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant patients are excluded.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Dose Level A

    EVE Treg Cell dose level A

    Biological: EVE-Treg

  • Experimental
    Dose Level B

    EVE Treg Cell dose level B

    Biological: EVE-Treg

  • Experimental
    Dose Level C

    EVE Treg Cell dose level C.

    Biological: EVE-Treg

Interventions

  • BiologicalEVE-Treg

    Ex Vivo-Expanded (EVE) Regulatory T cells.

07

What researchers measure

Primary outcomes

  1. Safety of EVE-Treg

    Safety of EVE-Treg, in combination with physician-prescribed daily low-dose IL-2, for the treatment of chronic GVHD refractory to steroids and low-dose IL-2. Safety will be based on adverse events at each Dose Level of EVE-Treg

    Time frame: 5 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 27, 2025
StartActual
May 29, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Leslie Kean→Sarah Nikiforow, MD
Oct 29, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date
  2. Oct 29, 2026
    Sponsor Leslie Kean→Sarah Nikiforow, MD
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06991361
Lead sponsor
Sarah Nikiforow, MD
Responsible party
Sarah Nikiforow, MD (Assistant Professor, Stem Cell Transplantation; Medical Director, DFCI Cell Manipulation Core Facility; Technical Director, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
May 27, 2025
Start date
May 29, 2026
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Brandi Bratrude
Contact
brandi.bratrude@childrens.harvard.edu
617-919-2197

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion